Eli Lilly and Incyte’s Olumiant (baricitinib) Receives the US FDA’s Breakthrough Therapy Designation for Alopecia Areata

 Eli Lilly and Incyte’s Olumiant (baricitinib) Receives the US FDA’s Breakthrough Therapy Designation for Alopecia Areata

Eli Lilly and Incyte’s OLUMIANT (baricitinib) Receives the US FDA’s Breakthrough Therapy Designation for Alopecia Areata

Shots:

  • The FDA’s BT designation is based on P-II results of P-II/III BRAVE-AA1 study assessing baricitinib vs PBO in patients with AA
  • The P-II portion of the BRAVE-AA1 study demonstrated no new safety signals with no SAEs @36wks. Additionally, P-III portion of BRAVE-AA1 & P-III BRAVE-AA2 study, are currently evaluating baricitinib (2mg/4mg) vs PBO in patients with AA
  • Olumiant is an approved treatment for adults with moderately to severely active RA, approved in ~65+ countries, including the US, member states of the EU and Japan

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post